Phase 2 Study to Evaluate Brincidofovir for the Prevention of Adenovirus Disease
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This study was designed to assess the safety and efficacy of preemptive treatment with oral
brincidofovir (BCV), as compared to placebo, for the prevention of adenovirus (AdV) disease
in recipients of hematopoietic stem cell transplantation (HCT) with asymptomatic AdV viremia.